| Source: AstraZeneca PLC
AstraZeneca today announced that Marc Dunoyer is to join the company in the
newly created role of Executive Vice President, Global Portfolio & Product

Marc will be responsible for driving business strategy, including business
development, mergers and acquisitions, portfolio and product strategies. His
most critical priorities will be to bolster the core growth platforms and
therapy areas through well executed business development initiatives and
leadership of internal efforts.

Marc will join AstraZeneca from GlaxoSmithKline (GSK) where, as Global Head of
Rare Diseases, he established an integrated global capability in treatments for
rare diseases from R&D through to commercialisation. He is also Chairman of GSK
Japan and a member of the Corporate Executive Team. Previously at GSK he was
President for Asia Pacific and Japan. Prior to joining GSK in 1999, Marc held a
number of international positions in operations and general management at
Hoechst Marion Roussel.

“I’m delighted Marc is joining us in this pivotal new role aimed at bringing
greater integration across our R&D, commercial and business development
activities,” said Pascal Soriot, Chief Executive Officer, AstraZeneca. “Marc is
a first-rate leader with a proven track record in driving business growth and he
brings to AstraZeneca a wealth of international operating experience, in
particular in the important Asia region, combined with outstanding strategic

Marc, who will join the company in the second quarter of 2013, will report to
Pascal Soriot and will be a member of AstraZeneca’s Senior Executive Team.

Marc has an MBA from the Hautes Etudes Commerciales and has a Bachelor of Law
degree from Paris University. He qualified as a Junior Certified Public
Accountant in France.

– ENDS –

To obtain a photograph of Marc Dunoyer please visit or contact the media team (details

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit:


Media Enquiries

|Esra Erkal-Paler|+44 20 7604 8030 (UK/Global)|
|Vanessa Rhodes  |+44 20 7604 8037 (UK/Global)|
|Ayesha Bharmal  |+44 20 7604 8034 (UK/Global)|
|Jacob Lund      |+46 8 553 260 20 (Sweden)   |

Investor Enquiries

|James Ward-Lilley|+44 20 7604 8122|mob: +44 7785 432613  |
|Karl Hård        |+44 20 7604 8123|mob: +44 7789 654364  |
|Colleen Proctor  |+ 1 302 886 4065|mob:   +1 302 373 1361|
|Ed Seage         |+ 1 302 886 1842|mob:   +1 302 357 4882|